[go: up one dir, main page]

AR055199A1 - Ligandos receptores de cannabinoides, composiciones farmaceuticas que los contienen y proceso para la preparacion de los mismos - Google Patents

Ligandos receptores de cannabinoides, composiciones farmaceuticas que los contienen y proceso para la preparacion de los mismos

Info

Publication number
AR055199A1
AR055199A1 ARP060102327A ARP060102327A AR055199A1 AR 055199 A1 AR055199 A1 AR 055199A1 AR P060102327 A ARP060102327 A AR P060102327A AR P060102327 A ARP060102327 A AR P060102327A AR 055199 A1 AR055199 A1 AR 055199A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
cycloalkenyl
independently
Prior art date
Application number
ARP060102327A
Other languages
English (en)
Inventor
Muthuppalniappan Meyyappan
Balasubramanian Gopalan
Gullapalli Srinivas
Khairatkar Joshi Neelima
Narayanan Shridhar
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AR055199A1 publication Critical patent/AR055199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Procesos de preparacion de dichos compuestos y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de formula (1), un análogo del mismo, una sal farmacéuticamente aceptable del mismo, un éster farmacéuticamente aceptable del mismo, un tautomero del mismo, un regioisomero del mismo, un estereoisomero del mismo, un enantiomero del mismo, a diastereomero del mismo, un polimorfo del mismo, o un solvato farmacéuticamente aceptable del mismo, en el cual cada una de las líneas punteadas en la formula (1) representa de manera independiente un doble enlace opcional; U y V son de manera independiente C o N; W, X e Y son de manera independiente C, N, O, S o -C(O)- siempre que al menos dos de entre U, V, W, X o Y se seleccionen de manera independiente de entre N, O, -C(O)- o S; R, R1 y R2 pueden ser idénticos o diferentes y son de manera independiente hidrogeno, nitro, ciano, formilo, acetilo, halogeno, -OR3, -SR3, oxo, tio, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, heteroarilalquilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, -NR3R4, -C(=B)-R3, - C(O)O-R3, -C(O)NR3R4, -S(O)m-R3, -S(O)m-NR3R4, o un grupo protector o R1 y R2 pueden estar unidos entre sí para formar un anillo cíclico saturado o no saturado de 3 a 7 miembros opcionalmente substituido, que opcionalmente puede incluir al menos dos heteroátomos seleccionados de entre O, NR3 o S; en cada aparicion de R3 y R4 pueden ser idénticos o diferentes y son de manera independiente hidrogeno, nitro, halo, ciano, -ORa, -SRa, oxo, tio, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo, cicloalquilalquilo, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, heteroarilalquilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, -C(=B)-Ra, -C(O) O-Ra, -C(O)NRaRb, -S(O)m-Ra, -S(O)m-NRaRb, -NRaRb, o un grupo protector o R3 y R4, cuando están unidos a un átomo comun, pueden estar unidos entre sí para formar un anillo cíclico saturado o no saturado de 3 a 7 miembros opcionalmente substituido, que opcionalmente puede incluir al menos dos heteroátomos seleccionados de entre O, NR3 o S; en cada aparicion Ra y Rb pueden ser idénticos o diferentes y son de manera independiente hidrogeno, halogeno, nitro, ciano, formilo, acetilo, oxo, tio, -C(O)-Rc, -C(O)O-Rc, - C(O)NRcRd, -S(O)m-Rc, -S(O)m- NRcRd, -NRcRd, -ORc, -SRc, un grupo protector, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, o heteroarilalquilo substituido o no substituido; en cada aparicion, Ra y Rb pueden ser idénticos o diferentes y son de manera independiente hidrogeno, halogeno, nitro, ciano, formilo, acetilo, oxo, tio, un grupo protector, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, o heteroarilalquilo substituido o no substituido; en cada aparicion, B es de manera independiente O, S o NR3; p y m son de manera independiente 0, 1 o 2; A tiene la estructura de (a) a (w) del grupo de formulas (2), en donde cada una de las líneas punteadas en A representan de manera independiente un doble enlace opcional; R5, R6, R7, R8, R9, R10, R11, R12, R13, y R14 son de manera independiente hidrogeno, nitro, ciano, formilo, acetilo, halogeno, - OR15, -SR15, oxo, tio, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, heteroarilalquilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, -NR15R16, -C(=B)-R15, -C(O)O-R15, -C(O)NR15R16 , -S(O)m-R15, -S(O)m-NR15R16, o un grupo protector; R5 y R6 pueden estar unidos entre sí para formar un anillo mono o bicíclico de 3 a 11 miembros saturado o no saturado opcionalmente substituido, que opcionalmente puede incluir al menos un heteroátomo seleccionado de entre O, NR3 o S; R9 y R10 pueden estar unidos entre sí para formar un anillo mono o bicíclico de 3 a 11 miembros saturado o no saturado opcionalmente substituido, que opcionalmente puede incluir al menos un heteroátomo seleccionado de entre O, NR3 o S; en cada aparicion, R15 y R16 pueden ser idénticos o diferentes y son de manera independiente hidrogeno, nitro, halo, ciano, -OR3, -SR3, oxo, tio, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, heteroarilalquilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, -C(=B)-R3, -C(O)O- R3, -C(O)NR3R4, -S(O)m-R3, -S(O)m-NR3R4, -NR3R4 o R15 y R16, cuando están unidos a un átomo comun, pueden estar unidos entre sí para formar un anillo cíclico saturado o no saturado de 3 a 7 miembros opcionalmente substituido, que opcionalmente puede incluir al menos dos heteroátomos seleccionados de entre O, NR3 o S; en donde R3 y R4 son tal como se define anteriormente; n es 1, 2, 3, o 4; y a, b, c, d y e son enteros seleccionados de manera independiente desde 0 a 4, siempre que el compuesto no tenga la formula (3) en el cual R1 y R2 son tal como se define anteriormente.
ARP060102327A 2005-06-02 2006-06-02 Ligandos receptores de cannabinoides, composiciones farmaceuticas que los contienen y proceso para la preparacion de los mismos AR055199A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN659MU2005 2005-06-02
US69643305P 2005-07-01 2005-07-01
IN1370MU2005 2005-10-31
IN344MU2006 2006-03-09
US74407106P 2006-03-31 2006-03-31
IN689MU2006 2006-05-03

Publications (1)

Publication Number Publication Date
AR055199A1 true AR055199A1 (es) 2007-08-08

Family

ID=37056437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102327A AR055199A1 (es) 2005-06-02 2006-06-02 Ligandos receptores de cannabinoides, composiciones farmaceuticas que los contienen y proceso para la preparacion de los mismos

Country Status (11)

Country Link
US (1) US8420689B2 (es)
EP (1) EP1902034B1 (es)
JP (1) JP2008545739A (es)
AR (1) AR055199A1 (es)
AU (1) AU2006253842A1 (es)
CA (1) CA2613678A1 (es)
MY (1) MY142409A (es)
PE (1) PE20070431A1 (es)
PL (1) PL1902034T3 (es)
TW (1) TW200716560A (es)
WO (1) WO2006129178A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP2010509201A (ja) * 2006-11-03 2010-03-25 グレンマーク・ファーマシューティカルズ・エスエー 新規なカンナビノイド受容体リガンド、およびこれらを含む薬剤組成物、およびこれらの調製方法
WO2008093194A1 (en) * 2007-01-29 2008-08-07 Glenmark Pharmaceuticals, S.A. Cannabinoid receptor modulators for treating non-immediate type allergic diseases
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102596913B (zh) * 2009-08-28 2016-11-09 艾尼纳制药公司 大麻素受体调节剂
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
ES2929977T3 (es) 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
BR112013021549B1 (pt) 2011-02-25 2022-01-11 Arena Pharmaceuticals, Inc Processos para preparação de forma cristalina anidra, para preparação de composição farmacêutica e para preparação de forma de dosagem, forma cristalina não solvatada anidra, composição farmacêutica, forma de dosagem, uso da referida forma cristalina e solvato
IN2014MN00226A (es) 2011-07-05 2015-09-25 Lupin Ltd
SG11201404214QA (en) 2012-02-03 2014-08-28 Teva Pharma USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
US10329259B2 (en) * 2014-05-09 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
RU2598077C1 (ru) * 2015-06-25 2016-09-20 Федеральное государственное бюджетное учреждение науки Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук Способ получения производных 1-пиразолина
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
EA201992638A1 (ru) 2017-05-08 2020-03-18 Арена Фармасьютикалз, Инк. Соединения и способы для лечения висцеральной боли
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
EP3853219B1 (de) 2018-09-19 2023-07-12 Bayer Aktiengesellschaft Herbizid wirksame substituierte phenylpyrimidinhydrazide
WO2021047583A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
US20240109910A1 (en) * 2019-10-09 2024-04-04 Janssen Pharmaceutica Nv HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND / OR CB2 RECEPTORS

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
JPH07196419A (ja) * 1994-01-05 1995-08-01 Sumitomo Chem Co Ltd シロアリ防除剤
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
AU735137B2 (en) 1997-02-21 2001-07-05 Bayer Intellectual Property Gmbh Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
WO1999002499A1 (en) 1997-07-11 1999-01-21 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
US6479479B2 (en) 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6355631B1 (en) 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
CN1205188C (zh) 2000-03-23 2005-06-08 索尔瓦药物有限公司 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物
AU2002256690B2 (en) 2001-03-22 2006-05-18 Solvay Pharmaceuticals B.V. 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US6974810B2 (en) 2001-09-21 2005-12-13 Solvay Pharmaceuticals B.V. 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
HUP0401567A3 (en) 2001-09-21 2005-06-28 Solvay Pharm Bv Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
WO2003027114A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
JP2005532982A (ja) 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
HRP20050044A2 (en) 2002-07-29 2005-10-31 F. Hoffmann - La Roche Ag Novel benzodioxoles
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
US7348456B2 (en) 2002-12-19 2008-03-25 Merck & Co., Inc. Substituted amides
FR2849032B1 (fr) 2002-12-23 2006-04-28 Sanofi Synthelabo Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
DE602004024880D1 (de) 2003-05-01 2010-02-11 Vernalis Res Ltd Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation

Also Published As

Publication number Publication date
PL1902034T3 (pl) 2011-09-30
JP2008545739A (ja) 2008-12-18
HK1118806A1 (en) 2009-02-20
WO2006129178A1 (en) 2006-12-07
TW200716560A (en) 2007-05-01
US8420689B2 (en) 2013-04-16
WO2006129178A8 (en) 2007-01-11
AU2006253842A1 (en) 2006-12-07
MY142409A (en) 2010-11-30
EP1902034A1 (en) 2008-03-26
EP1902034B1 (en) 2011-03-30
CA2613678A1 (en) 2006-12-07
PE20070431A1 (es) 2007-06-27
US20120142748A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
AR055199A1 (es) Ligandos receptores de cannabinoides, composiciones farmaceuticas que los contienen y proceso para la preparacion de los mismos
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR037182A1 (es) Compuestos del acido 4,5-disubstituido-n-acilpirrolidina-2-carboxilico, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y proceso para su fabricacion
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ECSP22050936A (es) Compuestos tric?clicos sustituidos
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
AR057543A1 (es) Derivados de benzofusionado sustituido utilizables como ligandos receptores de vainiloide
HRP20191901T1 (hr) Ciklizirani derivati sulfamoilarilamida i njihova uporaba kao lijekova za liječenje hepatitisa b
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR037181A1 (es) Compuesto de 4-heteroaril-(5-miembros) acil pirrolidina, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y procedimiento para su preparacion
AR041724A1 (es) Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas
RU2006139030A (ru) Ингибиторы gsk-3
AR069798A1 (es) Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
EP1829858A3 (en) Dibenzylamine compounds and pharmaceutical use thereof
AR061222A1 (es) Derivados de 2-oxo-piridina, 2-oxo-quinolina y 2-oxo-isoquinolina, composiciones farmaceuticas que los comprenden y el uso de los mismos en medicamentos para tratar enfermedades mediadas por la scd.
AR060508A1 (es) DERIVADOS DE QUINOLINA CON ACTIVIDAD INHIBITORIA DE LA CSF-1R QUINASA, UN METODO E INTERMEDIARIOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER.
AR105522A1 (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
PE20190800A1 (es) Derivados del heterociclo biciclico condensado como agentes de control de plagas
AR116474A1 (es) DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
AR107633A1 (es) Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
PE20240882A1 (es) Compuestos de 6-aminopirazolopirimidina y su uso medico
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
EP3502105A4 (en) POLYMORPHIC FORM OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREFOR AND PRODUCTION METHOD THEREFOR AND USE THEREOF
AR068888A1 (es) Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.

Legal Events

Date Code Title Description
FB Suspension of granting procedure